Previous 10 | Next 10 |
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jef...
2023-11-03 07:14:46 ET More on Morphic Morphic Holding: The Price Drop Is Very Interesting Biggest stock movers today: Cloudflare, NextEra Energy Partners, ChargePoint and more Morphic Holdings CEO Praveen Tipirneni takes temporary medical leave of absence Se...
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash...
2023-11-02 10:07:57 ET More on I-Mab, Morphic, etc. Morphic Holding: The Price Drop Is Very Interesting I-Mab: Why This Company Trades At A Third The Value Of Its Cash I-Mab (IMAB) Q2 2023 Earnings Call Transcript MorphoSys expects a 5% surge in Monjuvi sales...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Morphic Holding Inc. (MORF) is expected to report $-0.98 for Q3 2023
NEW YORK, NY / ACCESSWIRE / October 11, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF). Investors who purchased Morphic securities are encouraged to obtain additional info...
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complet...
ATLANTA, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF) complied with federal securities laws. On September 22, 2023, the Company released abstract data from its EME...
2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:MORF) on behalf of stockholders. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. If yo...
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside c...
-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclonal Antibody Activity- -Preclinical Findings Presented at Digestive Disease...